
    
      To examine lorcaserin a selective R-HT2c receptor antagonist approved by FDA as weight loss
      drug- for its ability to improve proprioceptive movements in patients with advanced
      colorectal cancer who developed neurotoxicity during oxaliplatin-based chemotherapy.
    
  